| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-06-24 | Moberg Pharma (Sweden) | € 0.9 million | grant | European Eurostars Programme (EU) | Infectious diseases | Grant |
| 2015-06-23 | Abivax (France) | €57.7 million | IPO | Infectious diseases | IPO | |
| 2015-06-23 | Advanced Accelerator Applications (France) | €23 million | financing round | Adage Capital Management (USA - MA) funds and accounts managed by T. Rowe Price Associates (USA - MD) and Rock Springs Capital Management (USA - MD) | Cancer - Oncology - Diagnostic - Technology - Services | Financing round |
| 2015-06-23 | bluebird bio (USA - MA) | $477.2 million | private placement | Rare diseases - Genetic diseases - Hematological diseases | Private placement | |
| 2015-06-23 | Biotie Therapies (Finland) | $56.6 million (€50,23 million) | IPO | Neurological diseases - Mental diseases | Establishment of a new subsidiary in the EU | |
| 2015-06-19 | Galapagos (Belgium) | €4.4 million | capital increase | Capital increase | ||
| 2015-06-17 | Amicus Therapeutics (USA - NJ) | $258.8 million | financing round | Rare diseases - Genetic diseases | Financing round | |
| 2015-06-16 | BioCardia (USA - CA) | Cardiovascular diseases | IPO | |||
| 2015-06-16 | Affiris (Austria) | € 10 million | capital increase | Santo Holding (Germany) MIG Verwaltungs AG (Germany) | Neurodegenerative diseases | Capital increase |
| 2015-06-16 | Axovant Sciences (Bermuda - USA - NY) | $362 million | IPO | Mental diseases - Neurodegenerative diseases | IPO | |
| 2015-06-15 | BioInvent (Sweden) | € 8.1 million | private placement | Private placement | ||
| 2015-06-12 | Atyr Pharma (USA - CA) | $ 75 million | IPO | Rare diseases | IPO | |
| 2015-06-11 | Oramed Pharmaceuticals (Israel) | $5.36 milion | private placement | Private placement | ||
| 2015-06-11 | Medgenics (USA - Israel) | $ 3.4 million | grant | Office of the Chief Scientist (OCS -Israel) | Rare diseases | Grant |
| 2015-06-10 | Melinta Therapeutics (USA - CT) | $67 million | financing round | Malin Corporation (Ireland) Vatera Healthcare Partners (USA - NY) other undisclosed existing investors | Infectious diseases | Financing round |
| 2015-06-10 | Melinta Therapeutics (USA - CT) | $67 million | series D financing round | Malin Corporation (Ireland) other existing investors, including Vatera Healthcare Partners.(USA - NY) | Infectious diseases | Series D financing round |
| 2015-06-03 | Auspherix (Australia) | £6 million | series A financing round | Imperial Innovations Group (UK) Medical Research Commercialisation Fund (MRCF) (Australia) | Infectious diseases | Series A financing round |
| 2015-06-02 | Intarcia Therapeutics (USA - CA) | $300 million | financing round | Metabolic diseases | Financing round | |
| 2015-05-28 | RXi Pharmaceuticals (USA - MA) | $10.4 million | private placement | Dermatological diseases - Ophtalmological diseases | Private placement | |
| 2015-05-27 | Fate Therapeutics (USA - CA) | $32 million | fundraising | Cancer - Oncology - Rare diseases - Genetic diseases - Hematological diseases | Fundraising |
